IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease:a Prospective Study

Recruiting

• Conditions: Crohn's Disease; Upadacitinib; Intestinal Ultrasound; Predictors

• Registration Number: NCT06573944
• Lead Sponsor: The Third Xiangya Hospital of Central South University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-24
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Inclusion Criteria:<br><br> - Age = 18 years and = 80 years;<br><br> - Patients with newly diagnosed or relapsed moderate to severe Crohn's disease<br><br> - Upadacitinib therapy is proposed to be applied within 1 month after baseline<br> endoscopy and intestinal ultrasound,;<br><br> - No history of abdominal surgery;<br><br> - Clearly understand, voluntarily participate in the study, and sign an informed<br> consent form.<br><br>Exclusion Criteria:<br><br> - Contraindications to upadacitinib: allergy, active tuberculosis or other active<br> infections, moderate-to-severe heart failure (NYHA grade III/ IV), demyelinating<br> lesions of the nervous system, live vaccination within the last 3 months, pregnancy<br> and lactation;<br><br> - Patients with a history of extensive colectomy or recent proposed colectomy, history<br> of colonic mucosal dysplasia;<br><br> - Hypersensitivity to the components of SonoVue contrast media.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bowel wall thickness (BWT)